ISR’s leading technology comprises a novel treatment for HIV/AIDS infected patients. A positive Phase I/IIa clinical trial has been completed on treatment naive HIV patients, and the company has an ongoing Phase II clinical trial on HIV patients on ART using the companies lead Immunorhelin compound ISR-48.
ISR is currently developing a second line of chemical entities, immunolides, were ISR-50 is the lead candidate, mowing forward to an investigational new drug (IND) for cancer and HBV.
Our mission is to find cures stimulating the immune system to fight infections and cancer.
At ISR we believe we have the breadth and depth of expertise required to ensure our vision becomes a reality.
Worldwide, 2 million new cases of HIV occurred in 2014. About 37 million people live with HIV but only 15 million have access to treatment. More than 200 million people are infected with HBV and there is no available cure.
Q&A Onkologi och Hepatit b